Roivant Sciences Receiving Interest in Bowel Disease Treatment, Bloomberg Says
Medication reportedly worth more than $7 billion.
Roivant Sciences, a biotechnology company, is reportedly garnering interest in its inflammatory bowel disease treatment from major pharmaceutical companies. Expected to be worth over $7 billion, the drug is also being tested for the treatment of ulcerative colitis and Crohn’s disease. While deliberations have focused mainly on the treatment, it’s possible the entire company could be sold as well, according to insiders, requesting not to be identified due to the matter not being public.
Presently, there is no deal in place as Roviant could elect to keep the treatment, the insiders stated.
Reference: Roivant Attracts Interest for $7 Billion-Plus Bowel Drug. Bloomberg. July 6, 2023. Accessed July 10, 2023. https://www.bloomberg.com/news/articles/2023-07-06/roivant-said-to-attract-interest-for-7-billion-plus-bowel-drug#xj4y7vzkg
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
